Literature DB >> 20347396

Association between Duffy antigen receptor for chemokines expression and levels of inflammation markers in sickle cell anemia patients.

Danitza Nebor1, Marie Claude Durpes, Danielle Mougenel, Martin Mukisi-Mukaza, Jacques Elion, Marie-Dominique Hardy-Dessources, Marc Romana.   

Abstract

Since inflammation plays a prominent role in the pathogenesis of sickle cell anemia (SCA) and Duffy antigen receptor for chemokines (DARC) modulates the function of inflammatory processes, we analyzed the relationship between the erythrocyte DARC phenotype and clinical expression of SCA. DARC locus was genotyped in 212 SS adult patients followed by the sickle cell center of Guadeloupe (French West Indies). After patients' stratification according to RBC DARC expression, the prevalence of renal disease, leg ulcers, priapism and osteonecrosis was compared between patient groups as well as hematological variables and plasma levels of chemokines. Duffy-positive patients exhibited higher counts of white blood cells (9.95+/-2.36 vs 8.88+/-2.32 10(9)/L, p=0.0066), polynuclear neutrophils (5.1+/-1.73 vs 4.51+/-1.71 10(9)/L, p=0.0227), higher plasma levels of IL-8 (4.46+/-1.22 vs 1.47+/-0.5 pg/mL, p=0.0202) and RANTES (27.8+/-4.3 vs 18.1+/-2.3 ng/mL, p=0.04) than Duffy-negative patients. No association was detected between RBC expression of DARC and the studied complications. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347396     DOI: 10.1016/j.clim.2010.02.023

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  13 in total

Review 1.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

2.  Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in U.S. hospital discharge records: a cross-sectional study.

Authors:  Mehdi Nouraie; Sergei Nekhai; Victor R Gordeuk
Journal:  Sex Transm Infect       Date:  2012-05-24       Impact factor: 3.519

Review 3.  Erythrocyte Duffy antigen receptor for chemokines (DARC): diagnostic and therapeutic implications in atherosclerotic cardiovascular disease.

Authors:  Stavros Apostolakis; Georgios K Chalikias; Dimitrios N Tziakas; Stavros Konstantinides
Journal:  Acta Pharmacol Sin       Date:  2011-03-28       Impact factor: 6.150

4.  Activation state of alpha4beta1 integrin on sickle red blood cells is linked to the duffy antigen receptor for chemokines (DARC) expression.

Authors:  Marie-Claude Durpès; Marie-Dominique Hardy-Dessources; Wassim El Nemer; Julien Picot; Nathalie Lemonne; Jacques Elion; Monique Decastel
Journal:  J Biol Chem       Date:  2010-11-18       Impact factor: 5.157

Review 5.  Minireview: Genetic basis of heterogeneity and severity in sickle cell disease.

Authors:  Alawi Habara; Martin H Steinberg
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-01

Review 6.  DARC and D6: silent partners in chemokine regulation?

Authors:  Chris A H Hansell; Catherine E Hurson; Robert J B Nibbs
Journal:  Immunol Cell Biol       Date:  2010-12-14       Impact factor: 5.126

7.  The effect of Duffy antigen receptor for chemokines on severity in sickle cell disease.

Authors:  Emma R Drasar; Stephan Menzel; Tony Fulford; Swee Lay Thein
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

Review 8.  Sickle Cell Anemia and Its Phenotypes.

Authors:  Thomas N Williams; Swee Lay Thein
Journal:  Annu Rev Genomics Hum Genet       Date:  2018-04-11       Impact factor: 9.340

Review 9.  Clinical biomarkers in sickle cell disease.

Authors:  Ghazi A Damanhouri; Jummanah Jarullah; Samy Marouf; S I Hindawi; Gohar Mushtaq; Mohammad A Kamal
Journal:  Saudi J Biol Sci       Date:  2014-09-18       Impact factor: 4.219

10.  MCP-1, KC-like and IL-8 as critical mediators of pathogenesis caused by Babesia canis.

Authors:  Asier Galán; Iva Mayer; Renata Barić Rafaj; Krešo Bendelja; Velimir Sušić; José Joaquín Cerón; Vladimir Mrljak
Journal:  PLoS One       Date:  2018-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.